bone growth News
-
Zetagen Therapeutics, Inc. Receives Patent for Regulation of Bone Growth and Bone Degradation Using Small-Molecule
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth using ZetaMet™ New patent further enhances the Company’s Global IP strategy Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to ...
-
Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ Company’s intellectual property pipeline targets other oncologic ...
-
Zetagen Therapeutics, Inc. Receives Australian Patent Issuance for Treatment of Stimulating Bone Growth
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions private, clinical-stage, ...
-
Nanovis Experiences Record High Sales in June 2020.
Carmel, Indiana (July 14, 2020) – Nanovis, a unique technology company focused on nanotechnology for improving bone growth and fighting infection, today reported a record sales month in June 2020. “I am inspired by the commitment and care demonstrated by our customers and our Nanovis Team in helping a record number of patients with Nanovis implants in June while also doing their ...
By Nanovis
-
Nanovis Announces Alpha Launch of the First and Only Bioceramic Nanotube-Enhanced Pedicle Screw System, Nano FortiFix
First use of a nanotechnology enhanced pedicle screw with label claims to increase and accelerate human osteoblast and mesenchymal stem cell calcified extracellular matrix production in vitro CARMEL, Ind., Sept. 28, 2021 - Nanovis, an award winning technology company with unique and differentiated nanotechnology surfaces for improving bone growth and fighting infection, is pleased to announce ...
By Nanovis
-
Zetagen Therapeutics, Inc. Receives Patents for Methods in Stimulating Bone Growth Using Small-Molecule
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions Zetagen Therapeutics, Inc., a ...
-
Cerapedics Announces Commercial Launch of i-FACTOR+ Matrix in Canada
Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. “We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, Chief Executive Officer of ...
-
Cerapedics Announces FDA approval of an IDE supplement
Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for the on-going clinical trial, ASPIRE, for P-15L Bone Graft in a single level transforaminal lumbar interbody fusion (TLIF) surgery. “We are pleased to announce ...
-
Cerapedics Announces Canadian Approval of its next-generation bone graft
Cerapedics, a private ortho-biologics company, today announced the Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix, making it the first market to approve the commercial launch of this product. “We are excited to announce Canadian regulatory approval of our next-generation product, based on P15 osteogenic cell-binding peptide , i-FACTOR+ ...
-
Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) supplement for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. Cerapedics requested approval for an updated package insert that ...
-
Nanovis Announces Commercial Launch of New Nanosurface Technology on Spinal Interbody Implants
CARMEL, Indiana. (July 30, 2019) – Nanovis today announced the commercial launch of its bioceramic nanotube enhanced FortiCore interbodies following a successful alpha launch. The FortiCore interbodies are designed with a unique, proprietary, patent protected bio-ceramic enhanced titanium nanotube surface. The nanotubes are applied to a deeply porous, fully interconnected titanium ...
By Nanovis
-
Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, announced today the completion of enrollment of the ASPIRE study, a pivotal U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study, to evaluate the safety and efficacy of P-15L Bone Graft for use in transforaminal lumbar interbody fusion (TLIF) surgery in patients with ...
-
Coming Soon – The next addition to the EMPOWR Platform
EMPOWR Acetabular™ is DJO’s modern, premium, intelligently designed acetabular system featuring advanced fixation technologies, efficient instrumentation, and a feature enabling future dual mobility offering.1 This system – combined with our femoral stem options which all have 12/14 robust micro-threaded trunnions – provides surgeons a comprehensive THA solution for all ...
-
Ankasa Regenerative Therapeutics Receives $8.5 Million in First Tranche of $17 Million Series A Financing Led by Avalon Ventures
Ankasa Regenerative Therapeutics, Inc. (Ankasa), a company focused on pharmaceutical preparations for reactivation of stem cells for organ and tissue regrowth, tissue repair and healing, has received $8.5 million in the first tranche of a $17 million Series A round of financing led by La Jolla-based Avalon Ventures. Other participants in the financing include Heraeus Medical, a global business ...
-
Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery
Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for patients undergoing ACDF surgery were recently published in ClinicoEconomics and Outcomes Research (July 2021, Volume 2021, Issue 13). In this landmark ...
-
Cerapedics Announces Results from Clinical Trial of i-FACTOR Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a ...
-
FDA Clears First Nanotechnology Peek Devices for Spinal Intervertebral Fusion
NASHUA, N.H.–(BUSINESS WIRE)–Vallum Corporation, a medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market a polyetheretherketone (PEEK) spinal interbody fusion device with a PEEKplus® nanotextured1 surface created by Vallum’s proprietary and patented Accelerated Neutral Atom Beam (ANAB) technology. ...
-
Nanovis Wins the Global Health & Pharma 2018 Technology Awards
CARMEL, Indiana. – Sept. 11, 2018 – Nanovis, a leader in nanomedicine for the spine, today announced a licensing agreement with the University of Nevada, Reno for a key nanosurface technology patent covering the use of ceramics on implants with nanopores. This foundational patent allows development of ceramics for medical implants with nanosurfacing that enhances cell binding and ...
By Nanovis
-
Molecular Matrix, Inc. Forms Strategic Alliance with Philosys Healthcare
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...
-
OSSIO Receives Vizient Contract for Bio-Integrative Orthopedic Fixation Technology
OSSIO, Inc., an orthopedic fixation technology company, today announced that it has received a contract with Vizient, Inc., making the company’s portfolio of bio-integrative OSSIOfiber products available at negotiated pricing to health care providers in Vizient’s group purchasing organization (GPO) under a three-year contract starting March 1. OSSIO’s contract with Vizient ...
By OSSIO Inc
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you